Statins: Common Perceptions Versus Clinical Reality in Women

Statins are widely prescribed medications, primarily known for their ability to lower cholesterol, particularly low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol.

The prevailing perception is that they are a cornerstone for preventing heart disease. However, when we delve into the comprehensive body of research, especially concerning women, a more complex picture emerges.

What are the common misconceptions about statins in women?

• Primary Prevention of Heart Disease: While statins are often considered the treatment of choice for coronary artery disease (CAD) prevention, numerous studies indicate they do not provide strong support for their use in primary prevention of heart disease in women. In fact, the data supporting their use for primary prevention in women is described as "limited," essentially meaning no benefit compared to men. This is a critical distinction often overlooked.

• Reduction in Overall Mortality: Despite their widespread use, cumulative data from several large trials do not show that statins significantly reduce total mortality. While they may reduce cardiovascular events by a small margin (typically 2-3% in absolute terms), this does not consistently translate to a reduction in overall deaths.

• Plaque Regression: It's a common assumption that statins actively reverse plaque buildup in arteries. However, studies consistently show that statins increase coronary artery calcium (CAC). While this increase in calcification is sometimes interpreted as plaque stabilization, the fact remains that statins typically do not reverse plaque or CAC; rather, they can lead to its progression. Any observed reduction in plaque has been minimal and often requires highly specialized endovascular measurements.

What are the under-appreciated harms, or "collateral damage," of statins?

• Increased Risk of Type 2 Diabetes: This is a well-documented concern. People taking statins have shown a significantly increased risk of developing new cases of type 2 diabetes, with some meta-analyses reporting a 44% increased risk and long-term use (15-20 years) associated with a 363% increased risk. The mechanism involves impaired insulin secretion by pancreatic beta cells and worsening insulin resistance in the periphery. This is particularly concerning given that insulin resistance itself contributes to various chronic diseases.

• Increased Risk of Cancers: Multiple studies, including randomized controlled trials, show an increased risk for breast cancer and colon cancer with statin use. This risk is often comparable to, or even greater than, that associated with certain hormone therapies, yet it's frequently unmentioned.

• Adverse Impact on Lipid Profiles: While statins lower LDL, they can paradoxically increase triglycerides and lower beneficial HDL cholesterol. This is counterproductive, as a high triglyceride-to-HDL ratio is a strong predictor of heart disease.

• Increased Visceral Fat: Statins can contribute to an increase in visceral fat. This is significant because visceral fat is a major driver of inflammation and insulin resistance, which are root causes of many chronic diseases.

• Microvascular Complications: Existing evidence shows statins primarily benefit macrovascular complications (like major heart attacks or strokes) but not microvascular complications. This is particularly relevant given that microvascular issues exacerbate conditions like Alzheimer's disease.

• Impact on Hormones: Statins can lower testosterone levels, which are crucial for overall metabolic health in both men and women.

Why are these risks often not disclosed?

The discussion around statins often highlights "benefits outweighing the risks". However, this often focuses solely on the reduction in major cardiovascular events (often a relative risk reduction, which can inflate perceived benefit), while overlooking the significant collateral damage mentioned above. Regulatory agencies like the FDA do not recommend short-term use for statins, nor do cardiologists routinely inform patients of risks like increased breast cancer or diabetes, unlike the scrutiny applied to hormone therapies. This disparity in informed consent is a critical issue.

Better Alternatives and Complementary Strategies: Optimizing Your Endogenous Hormones

Given these profound insights, the question arises: what are the better alternatives, especially since the loss of hormones, particularly estrogen at menopause, itself contributes to cardiovascular risk, dyslipidemia, insulin resistance, and increased visceral fat?

Instead of solely relying on statins, or in conjunction with them to mitigate their "collateral damage," a wealth of evidence supports the optimization of key hormones:

- Estradiol (E2): The Foundational Hormone

• Unparalleled Cardiovascular Protection: Estradiol, particularly when initiated early in menopause (under age 60 or within 10 years of menopause), offers significant reduction in coronary heart disease events and overall mortality (up to 50% in some studies), a benefit not seen with any other drug.

• Plaque Reversal and CAC Reduction: Unlike statins, oral estradiol has been shown to reduce and even reverse atherosclerotic plaque and decrease coronary artery calcium scores.

• Improved Lipid Profile: Oral estradiol significantly raises beneficial HDL cholesterol, lowers LDL cholesterol, and favorably impacts other key lipid markers that statins do not.

• Diabetes and Insulin Resistance Prevention/Improvement: Estradiol helps decrease insulin resistance, lower blood sugar, and reduce the risk of type 2 diabetes.

• Breast Cancer Risk Reduction: Contrary to persistent misconceptions, studies demonstrate that estrogen (specifically estradiol alone) decreases the incidence and mortality of breast cancer.

• Visceral Fat Reduction: Estradiol contributes to a decrease in visceral fat.

• Oral vs. Transdermal: While transdermal estradiol is considered safer in terms of blood clot risk in older women or those with pre-existing conditions, oral estradiol offers superior cardiovascular benefits, particularly for lipid modification and plaque reversal, due to its first-pass effect through the liver. It is crucial to differentiate estradiol from Premarin (conjugated equine estrogens), as most negative studies on "estrogen" used Premarin, which has a different risk profile and often includes synthetic progestins like Provera.

- Micronized Progesterone:

• This natural hormone has beneficial effects on the cardiovascular system and is not associated with the fear of using it in progesterone-positive tumors, as it actually stimulates tumor cell death. It is crucial to distinguish it from synthetic progestins (like Provera), which have been associated with increased risks of breast cancer, heart attacks, strokes, and blood clots, and can negate estrogen's benefits. Micronized progesterone also supports mood stability.

- Testosterone:

• In women, testosterone and DHEA can inhibit breast cancer development and growth. Testosterone therapy significantly improves all components of the metabolic syndrome, leading to weight loss, decreased waist circumference, and improved glycemic control, blood pressure, and lipids (including raising HDL and lowering triglycerides). There's no association between testosterone use and increased risk of blood clots, strokes, or heart attacks in numerous studies.

- Thyroid Hormone (T3):

• Optimizing free T3 levels, even when TSH is considered "normal," can dramatically improve lipids (lowering LDL and raising HDL), lower blood sugar, reduce visceral fat, and enhance overall metabolism and energy.

- DHEA:

• Administration of DHEA has been shown to reduce visceral fat accumulation and protect against insulin resistance, with a significant increase in insulin sensitivity.

- Melatonin:

• Melatonin supplementation can reduce serum glucose, increase insulin sensitivity, decrease inflammatory markers (like C-reactive protein), and reduce visceral fat.

- Spironolactone:

• This medication can reduce elevated aldosterone levels, which are linked to inflammation and blood pressure, particularly in conditions like PCOS. It can also improve skin health.

In my clinical practice, and supported by a deep understanding of the scientific literature, the approach to cardiovascular health, especially in women, necessitates a shift from a "cholesterol-centric" view to a holistic, hormone-optimizing strategy. While statins remain an option for secondary prevention, particularly in specific indications, it's crucial to acknowledge their limitations and potential collateral damage. The profound protective effects of optimized hormones, often able to reverse the very pathology statins struggle to address, present a compelling and evidence-based alternative or complementary strategy that is unfortunately underutilized and often misunderstood within conventional medicine.

Ultimately, empowering patients with this knowledge allows for true shared decision-making, where the full spectrum of benefits and risks from all available therapies, including hormone optimization, can be thoroughly considered.

- Luke Swift, DNP, APN-FPA, PMHNP-BC, ABHRT